期刊
ADDICTION
卷 103, 期 6, 页码 1048-1050出版社
WILEY
DOI: 10.1111/j.1360-0443.2008.02209.x
关键词
dependence; kratom; molecular screening; opioid; opioid replacement; withdrawal
资金
- NCRR NIH HHS [P20 RR021929, P20RR021929] Funding Source: Medline
- NIDA NIH HHS [R21 DA022677, R21 DA014929, DA014929, DA022677] Funding Source: Medline
Background Kratom (Mitragynia speciosa korth) is recognized increasingly as a remedy for opioid withdrawal by individuals who self-treat chronic pain. Case description A patient who had abruptly ceased injection hydromorphone abuse self-managed opioid withdrawal and chronic pain using kratom. After co-administering the herb with modafinil he experienced a tonic-clonic seizure, but he reported only modest abstinence once kratom administration stopped. We confirmed the identity of the plant matter he ingested as kratom and identified no contaminants or adulterants. We also conducted high-throughput molecular screening and the binding affinity at mu, delta and kappa receptors of mitragynine. Conclusion We report the self-treatment of chronic pain and opioid withdrawal with kratom. The predominant alkaloid of kratom, mitragynine, binds mu- and kappa-opioid receptors, but has additional receptor affinities that might augment its effectiveness at mitigating opioid withdrawal. The natural history of kratom use, including its clinical pharmacology and toxicology, are poorly understood.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据